In ER or PgR positive BC patients, mPFS2 was 7 months (95% CI, 4–10) if treated with second‐line T‐DM1, while it was 5 months (95% CI, 3–7) if treated with another regimen (p = 0.05). This evidence concerns the gene PGR and breast cancer.